Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2b study of clazakizumab for reducing hsCRP in adults with elevated hsCRP and established or high-risk ASCVD
jRCT2031260463Phase 2Recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Aug 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 2, randomised, double-blind trial of clazakizumab in atherosclerotic disease, obesity, hypertension (HTN) and 2 more (4 arms), sponsored by Eli Lilly and Company. Primary endpoint: Percent change from baseline in hsCRP. Started Aug 2026; status: recruiting.
02
Drugs
clazakizumab
03
Conditions
atherosclerotic diseaseobesityhypertension (HTN)type 2 diabetes mellitus (T2DM)chronic kidney disease (CKD)
Beyond the preview
Go deeper on jRCT2031260463.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031260463.